Astellas Reports 17.3% Sales Growth in First Nine Months of FY2022, with Greater China Up 29.4%

News on February 7: Astellas Pharma, Inc. recently released its global financial results for the first nine months of the fiscal year 2022 (from April 1, 2022, to December 31, 2022). The sales revenue for the first nine months of the fiscal year 2022 was 1.16 trillion yen, representing a year-on-year increase of 17.3% compared to the same period of the previous fiscal year, with a core operating profit of 233.7 billion yen. Among the major products driving this growth are XTANDI for prostate cancer treatment, XOSPATA for acute myeloid leukemia treatment, and PADCEV for urothelial cancer treatment. Additionally, the Greater China region achieved revenue of 65.2 billion yen, marking a year-on-year increase of 29.4%.